ADCs are empowered antibodies designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents to overcome toxicity issues. One of the major limitations of ADCs is having an appropriate linker.
The proposed technology improves the linker, making it possible to create an ADC that possesses high specificity and the advantages of macromolecular therapeutics. The technology involves a controlled living polymerization technique that results in a well-defined HPMA polymer-drug conjugate, followed by specific attachment to an antibody to generate a homogenous ADC with an adjustable amount of payload. Lead ADC, RTX-P-EPI (Rituximab conjugated to Epirubicin) has been well characterized for high linker stability, homogenous ADC mixture, and ADC internalization.